Baseline characteristics and enrichment results from the SONAR trial.

Hiddo J Lambers HeerspinkDennis L AndressGeorge L BakrisJohn J BrennanRicardo Correa-RotterFan Fan HouDalane W KitzmanDonald KohanHirofumi MakinoJohn Joseph Valentine McMurrayVlado PerkovicSheldon TobeMelissa WigdersonTingting YiHans-Henrik ParvingDick de Zeeuw

Published in: Diabetes, obesity & metabolism (2018)

The enrichment period has successfully identified a population with a profound UACR reduction without clinical signs of sodium retention in whom a large atrasentan effect on clinically important renal outcomes is possible. The SONAR trial aims to establish whether atrasentan confers renal protection.

Keyphrases

phase iii
study protocol
phase ii
clinical trial
open label
intellectual disability
autism spectrum disorder
insulin resistance